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To the Editor:
In a recent article by Chachques and asso-
ciates,1 the authors compared locally deliv-
ered vascular endothelial growth factor
(VEGF) administration versus isolated or
combined delivery of skeletal myoblasts
and VEGF in an ovine model of myocar-
dial infarction. The investigators demon-
strated decreased left ventricular dilation
and improved contractility (regional frac-
tional area change) regardless of VEGF
administration. The author concluded that
“further studies are warranted on prevascu-
larization of myocardial scars with angio-
genic therapy.”
In the April 2004 issue of this journal,
we demonstrated improved survival of
transplanted fetal cardiomyocytes in a rat
infarct model and improved exercise toler-
ance of these animals with pretreatment of
the infarct with VEGF 3 weeks before cell
implantation.2 We used this delayed inter-
val, based on our earlier studies examining
the angiogenic effects of VEGF,3 because
we believed that it would allow critical
time for angiogenesis to develop, thereby
providing perfusion and supporting the sur-
vival of subsequently implanted cells.
We have subsequently duplicated these
findings by using skeletal myoblast implan-
tation. In these animals, the left ventricular
ejection fraction was significantly im-
proved in rats that were pretreated with
VEGF and that later received skeletal myo-
blast transplants compared with control an-
imals that received cells alone or VEGF
scular Surgery ● March 2005and cells as a simultaneous treatment. This
is noteworthy in that skeletal myoblasts
have been perceived to be “hardier” than
fetal cardiomyocytes or other cell implant
types, but angiogenic pretreatment proved
to be beneficial in this case as well.
In light of our findings, we agree with
Chachques and colleagues and believe that
angiogenic pretreatment may be a critical
component of cellular cardiomyoplasty
strategies for the treatment of myocardial
infarction.
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